Tech Company Financing Transactions

Ikena Oncology Funding Round

Omega Funds, Atlas Venture and Bristol-Myers Squibb joined a $120 million Series B capital raise for Ikena Oncology. The round was announced on 1/6/2021.

Transaction Overview

Company Name
Announced On
1/6/2021
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series B
Proceeds Purpose
Ikena intends to use the proceeds from this financing to advance its pipeline of targeted oncology therapies, including its novel development candidate TEAD inhibitor IK-930, and a new first-in-class preclinical program targeting KRAS signaling.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
50 Northern Ave. 7th Floor
Boston, MA 02210
USA
Email Address
Overview
Ikena envisions a world where every cancer patient has a cure. Ikena, headquartered in the biotech hub of Boston, Massachusetts, is dedicated to bringing next generation targeted oncology and immunometabolism therapies to patients suffering from cancer.
Profile
Ikena Oncology LinkedIn Company Profile
Social Media
Ikena Oncology Company Twitter Account
Company News
Ikena Oncology News
Facebook
Ikena Oncology on Facebook
YouTube
Ikena Oncology on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Manfredi
  Mark Manfredi LinkedIn Profile  Mark Manfredi Twitter Account  Mark Manfredi News  Mark Manfredi on Facebook
Chief Financial Officer
Douglas Carlson
  Douglas Carlson LinkedIn Profile  Douglas Carlson Twitter Account  Douglas Carlson News  Douglas Carlson on Facebook
Chief Medical Officer
Sergio Santillana
  Sergio Santillana LinkedIn Profile  Sergio Santillana Twitter Account  Sergio Santillana News  Sergio Santillana on Facebook
Chief Scientific Officer
Jeffrey Ecsedy
  Jeffrey Ecsedy LinkedIn Profile  Jeffrey Ecsedy Twitter Account  Jeffrey Ecsedy News  Jeffrey Ecsedy on Facebook
Vice President
Alfredo Castro
  Alfredo Castro LinkedIn Profile  Alfredo Castro Twitter Account  Alfredo Castro News  Alfredo Castro on Facebook
Vice President
Alexander Constan
  Alexander Constan LinkedIn Profile  Alexander Constan Twitter Account  Alexander Constan News  Alexander Constan on Facebook
Vice President
Karen McGovern
  Karen McGovern LinkedIn Profile  Karen McGovern Twitter Account  Karen McGovern News  Karen McGovern on Facebook
VP - Bus. Development
Maude Tessier
  Maude Tessier LinkedIn Profile  Maude Tessier Twitter Account  Maude Tessier News  Maude Tessier on Facebook
VP - Manufacturing
James Nolan
  James Nolan LinkedIn Profile  James Nolan Twitter Account  James Nolan News  James Nolan on Facebook
VP - R & D
Michelle Zhang
  Michelle Zhang LinkedIn Profile  Michelle Zhang Twitter Account  Michelle Zhang News  Michelle Zhang on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/6/2021: BayoTech venture capital transaction
Next: 1/6/2021: Terns Pharmaceuticals venture capital transaction

 

Share this article

 


About Database of VC Transactions

Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary